Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 16/20 | 0.61 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.61 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.61 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.61 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841909 | 0.89 | GRIA4 (0.59) | GRIA4GRIA2GRIA1GRIA3ACACB | |
| SCHEMBL6846283 | 0.87 | GRIA4 (0.56) | GRIA4GRIA2GRIA1GRIA3ACACB | |
| SCHEMBL6842002 | 0.86 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3ACACB | |
| SCHEMBL6847246 | 0.83 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3ACACB | |
| SCHEMBL5877677 | 0.82 | GRIA4 (0.68) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6846390 | 0.82 | GRIA4 (0.56) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565117 | 0.82 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6841983 | 0.81 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3 | |
| Hydrochloric Acid SCHEMBL6848818 | 0.81 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6847607 | 0.81 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-07 | — | — | US | claimed |
| EP-1315696-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-06-04 | — | — | EP | claimed |
| WO-2002018329-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | claimed |
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 11/4885GRIA2 9/4885GRIA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.